Fibrinolysin

"Fibrinolysin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.

Descriptor ID	D005341
MeSH Number(s)	D08.811.277.656.300.760.330 D08.811.277.656.959.350.330
Concept/Terms	Fibrinolysin Fibrinolysin Plasmin Protease F Glu-Plasmin Glu Plasmin Fibrogammin Fibrogammin Thrombolysin Thrombolysin

Below are MeSH descriptors whose meaning is more general than "Fibrinolysin".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Hydrolases [D08.811.277]
Peptide Hydrolases [D08.811.277.656]
Endopeptidases [D08.811.277.656.300]
Serine Endopeptidases [D08.811.277.656.300.760]
Fibrinolysin [D08.811.277.656.300.760.330]
Serine Proteases [D08.811.277.656.959]
Serine Endopeptidases [D08.811.277.656.959.350]
Fibrinolysin [D08.811.277.656.959.350.330]

Below are MeSH descriptors whose meaning is more specific than "Fibrinolysin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Fibrinolysin" by people in this website by year, and whether "Fibrinolysin" was a major or minor topic of these publications.

Bar chart showing 26 publications over 14 distinct years, with a maximum of 8 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1998	1	0	1
2000	1	0	1
2008	1	0	1
2009	0	1	1
2010	1	0	1
2012	2	0	2
2013	1	0	1
2014	1	1	2
2015	8	0	8
2016	1	0	1
2018	2	1	3
2020	1	1	2
2021	0	1	1

Below are the most recent publications written about "Fibrinolysin" by people in Profiles.

Jackson TL, Haller J, Blot KH, Duchateau L, Lescrauwaet B. Ocriplasmin for treatment of vitreomacular traction and macular hole: A systematic literature review and individual participant data meta-analysis of randomized, controlled, double-masked trials. Surv Ophthalmol. 2022 May-Jun; 67(3):697-711.

View in: PubMed
Mein C, Dugel PU, Feiner L, Drenser K, Miller D, Benz M, Meunier E, Moro L, Fineman MS. PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY. Retina. 2020 Jul; 40(7):1331-1338.

View in: PubMed
Khanani AM, Dugel PU, Haller JA, Wagner AL, Lescrauwaet B, Schmidt R, Bennison C. Cost-effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US. J Comp Eff Res. 2020 03; 9(4):287-305.

View in: PubMed
Yu TM, Dugel PU, Haller JA, Kaiser PK, Arnold RJ. Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA. J Comp Eff Res. 2018 12; 7(12):1195-1207.

View in: PubMed
McAleer MA, Jakasa I, Raj N, O'Donnell CPF, Lane ME, Rawlings AV, Voegeli R, McLean WHI, Kezic S, Irvine AD. Early-life regional and temporal variation in filaggrin-derived natural moisturizing factor, filaggrin-processing enzyme activity, corneocyte phenotypes and plasmin activity: implications for atopic dermatitis. Br J Dermatol. 2018 08; 179(2):431-441.

View in: PubMed
Birch DG, Benz MS, Miller DM, Antoszyk AN, Markoff J, Kozma P, Meunier E, Sergott RC. EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT: Results of the OASIS Trial ERG Substudy. Retina. 2018 Feb; 38(2):364-378.

View in: PubMed
Jackson TL, Regillo CD, Girach A, Dugel PU. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin. Ophthalmic Surg Lasers Imaging Retina. 2016 08 01; 47(8):716-23.

View in: PubMed
Greven MA, Garg S, Chiu B, Shah SP, Wolfe J, Fine HF, Roth DB, Robinson J, Mong J, Hsu J, Regillo C, Ho A, Haller JA. Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study. Br J Ophthalmol. 2016 Sep; 100(9):1211-5.

View in: PubMed
Khan MA, Shahlaee A, Ho AC. Reopening of a Full-Thickness Macular Hole 2 Years After Pharmacologic Closure With Ocriplasmin. JAMA Ophthalmol. 2015 Nov; 133(11):1362-4.

View in: PubMed
Varma R, Haller JA, Kaiser PK. Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials. JAMA Ophthalmol. 2015 Sep; 133(9):997-1004.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement